Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/03/2026 GMT			5-day change	1st Jan Change
247.05 ^DKK	+0.02%		-0.34%	-24.04%

03-14	How are different indices influenced?
03-13	Form Health Joins Lilly Employer Connect Platform	CI

NOVO NORDISK : Barclays reiterates its Neutral rating

Published on 02/13/2026 at 11:45 am GMT

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

+0.02%

In a research note published by James Gordon, Barclays gives a Neutral rating to the stock. The target price is reduced from DKK 360 to DKK 340.

Latest news about Novo Nordisk A/S

03-14	How are different indices influenced?
03-13	Form Health Joins Lilly Employer Connect Platform	CI
03-13	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-13	Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots	RE
03-12	Unifor Local 27 ratifies three-year agreement with Catalent	RE
03-12	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-12	Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit	MT
03-12	Berenberg cuts Novo Nordisk price target on Cagrisema outlook - BN	FW
03-12	Tellus Midas declined 1.30 percent in February - increased cash position	FW
03-12	Novo Nordisk Price Target Cut as Berenberg Expects Lower CagriSema Sales Amid Recent Clinical Data	MT
03-12	Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks	RE
03-12	Former Novo Executive Camilla Sylvest Nominated to Getinge Board	FW
03-12	Berenberg lowers price target for Novo Nordisk to 300 Danish kroner (360), reiterates buy - BN	FW
03-12	NOVO NORDISK : Receives a Buy rating from Berenberg	ZD
03-12	Nordic Stocks in North America - Astra Zeneca Rose 0.7 Percent	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

03-27 - Ex-dividend date - 7.95 DKK

More about the company